An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio‐oedema

Reduced levels of serum C4 have been considered a ubiquitous finding in hereditary angio‐oedema (HAE), and consequently low C4 is often used to ‘request manage’ access to C1 inhibitor assays in the United Kingdom. However, in our experience normal C4 may occasionally be compatible with HAE. We audited the results of serum C4, C1 inhibitor antigen (C1inhA) and C1 inhibitor function (C1inhF) in 49 HAE patients, compared to a control group of 58 unaffected subjects. The sensitivity of low serum C4 for HAE among untreated patients was 81%; levels of complement C4 were within the normal range on nine separate occasions in five untreated HAE patients. Molecular genetic analysis of these individuals demonstrated novel mutations in the C1 inhibitor gene. The supplied reference ranges for the Quidel C1inhF enzyme‐linked immunosorbent assay (ELISA) system appear to be too low, with a sensitivity of just 57% for HAE. Following optimization of the reference ranges using receiver operating characteristic analysis, low C1inhF was found to be 78% sensitive and 100% specific for HAE. The diagnosis of HAE is not excluded by normal levels of complement C4. We conclude that C1 inhibitor studies should be performed regardless of serum C4 where a high index of clinical suspicion exists.

[1]  M. Gompels,et al.  Laboratory testing for C1 inhibitor deficiency: a comparison of two approaches to C1 inhibitor function , 2007, Annals of clinical biochemistry.

[2]  M. Gompels,et al.  C1 inhibitor deficiency: diagnosis , 2005, Clinical and experimental dermatology.

[3]  H. Longhurst Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.

[4]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[5]  H. Griffiths,et al.  Normal complement C4 values do not exclude hereditary angioedema , 2004, Journal of Clinical Pathology.

[6]  M. Gompels,et al.  A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. , 2002, Journal of clinical pathology.

[7]  M. Tosi Molecular genetics of C1 inhibitor. , 1998, Immunobiology.

[8]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[9]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[10]  A. Sheffer,et al.  Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[11]  M. Cicardi,et al.  Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. , 1980, The Journal of allergy and clinical immunology.

[12]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[13]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[14]  A. Sheffer,et al.  Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.